A detailed history of Susquehanna International Group, LLP transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Susquehanna International Group, LLP holds 386,430 shares of MREO stock, worth $1.29 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
386,430
Previous 840,264 54.01%
Holding current value
$1.29 Million
Previous $3.02 Million 47.49%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.45 - $4.87 $1.57 Million - $2.21 Million
-453,834 Reduced 54.01%
386,430 $1.59 Million
Q2 2024

Aug 15, 2024

SELL
$2.58 - $4.25 $2.01 Million - $3.31 Million
-779,363 Reduced 48.12%
840,264 $3.02 Million
Q1 2024

May 07, 2024

BUY
$2.3 - $4.05 $3.32 Million - $5.85 Million
1,443,999 Added 822.19%
1,619,627 $5.34 Million
Q4 2023

Feb 14, 2024

BUY
$1.19 - $2.42 $86,106 - $175,106
72,358 Added 70.07%
175,628 $405,000
Q3 2023

Nov 14, 2023

BUY
$1.15 - $1.67 $118,760 - $172,460
103,270 New
103,270 $133,000
Q1 2023

May 16, 2023

BUY
$0.71 - $1.22 $21,292 - $36,586
29,989 Added 228.92%
43,089 $30,000
Q4 2022

Feb 14, 2023

SELL
$0.5 - $1.01 $19,412 - $39,213
-38,825 Reduced 74.77%
13,100 $9,000
Q3 2022

Nov 14, 2022

SELL
$0.82 - $1.73 $12,426 - $26,216
-15,154 Reduced 22.59%
51,925 $45,000
Q2 2022

Aug 15, 2022

BUY
$0.33 - $1.69 $1,696 - $8,689
5,142 Added 8.3%
67,079 $75,000
Q4 2021

Feb 14, 2022

BUY
$1.51 - $2.59 $35,266 - $60,489
23,355 Added 60.53%
61,937 $99,000
Q3 2021

Nov 15, 2021

BUY
$2.2 - $3.17 $38,396 - $55,326
17,453 Added 82.6%
38,582 $93,000
Q2 2021

Aug 11, 2021

BUY
$2.94 - $4.08 $15,214 - $21,114
5,175 Added 32.44%
21,129 $67,000
Q1 2021

May 17, 2021

BUY
$2.6 - $4.43 $41,480 - $70,676
15,954 New
15,954 $54,000

Others Institutions Holding MREO

About Mereo Biopharma Group plc


  • Ticker MREO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,986,000
  • Market Cap $419M
  • Description
  • Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...
More about MREO
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.